NASDAQ: BCLIBrainstorm Cell Therapeutics Inc Stock
$1.09-0.03 (-2.68%)
Updated Apr 29, 2025
BCLI Price
$1.09
Fair Value Price
$1.98
Market Cap
$7.08M
52 Week Low
$0.72
52 Week High
$10.05
P/E
-0.47x
P/B
-0.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.62M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.24
Operating Cash Flow
-$9M
Beta
0.72
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BCLI Overview
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BCLI's potential to beat the market
- BCLI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BCLI
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important BCLI news, forecast changes, insider trades & much more!
BCLI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BCLI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCLI ($1.09) is undervalued by 45.19% relative to our estimate of its Fair Value price of $1.98 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BCLI ($1.09) is significantly undervalued by 45.19% relative to our estimate of its Fair Value price of $1.98 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BCLI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCLI due diligence checks available for Premium users.
Valuation
BCLI fair value
Fair Value of BCLI stock based on Discounted Cash Flow (DCF)
Price
$1.09
Fair Value
$1.98
Undervalued by
44.94%
BCLI ($1.09) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCLI ($1.09) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCLI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCLI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.47x
Industry
-158.75x
Market
29.19x
BCLI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.91x
Industry
4.37x
BCLI's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.0M
Profit Margin
0%
BCLI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.8M
Liabilities
$9.6M
Debt to equity
-1.24
BCLI's short-term liabilities ($8.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCLI's long-term liabilities ($618.00k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCLI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCLI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
$12.0k
Financing
$1.1M
BCLI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCLI vs Biotech Stocks
Brainstorm Cell Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.